GPI/AMF inhibition blocks the development of the metastatic phenotype of mature multi-cellular tumor spheroids  by Gallardo-Pérez, Juan Carlos et al.
Biochimica et Biophysica Acta 1843 (2014) 1043–1053
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrGPI/AMF inhibition blocks the development of the metastatic phenotype
of mature multi-cellular tumor spheroidsJuan Carlos Gallardo-Pérez a, Nadia Alejandra Rivero-Segura a, Alvaro Marín-Hernández a,
Rafael Moreno-Sánchez a, Sara Rodríguez-Enríquez a,b,⁎
a Departamento de Bioquímica, Instituto Nacional de Cardiología, Tlalpan, México DF 14080, México
b Laboratorio de Medicina Traslacional, Instituto Nacional de Cancerología, MéxicoAbbreviations: EGF, epidermal growth factor; EMT, e
tion; ERI4P, erythrose-4-phosphate; b-FGF, basic ﬁb
hepatocyte-derived growth factor; GPI/AMF, glucose phos
tility factor; LDH, lactate dehydrogenase; MMP-1, matri
multi-cellular tumor spheroids; PRL, proliferative cell la
TGF-β, transforming growth factor-β; VEGF, vascular end
phosphogluconate
⁎ Corresponding author at: Instituto Nacional de C
Bioquímica, Juan Badiano No. 1, Col. Sección XVI, Tlalp
Tel.: +52 5552-55732911x1422; fax: +52 5552 5573092
E-mail address: saren960201@hotmail.com (S. Rodríg
0167-4889/$ – see front matter © 2014 Published by Else
http://dx.doi.org/10.1016/j.bbamcr.2014.01.013a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 November 2013
Received in revised form 8 January 2014
Accepted 10 January 2014
Available online 16 January 2014
Keywords:
Epithelial–mesenchymal transition
Cell migration
Invasiveness
Metastatic phenotype
Glucose phosphate isomerase/autocrine
motility factor
Tumor spheroidEpithelial–mesenchymal transition (EMT) and cellular invasiveness are two pivotal processes for the develop-
ment of metastatic tumor phenotypes. The metastatic proﬁle of non-metastatic MCF-7 cells growing as multi-
cellular tumor microspheroids (MCTSs) was analyzed by determining the contents of the EMT, invasive and
migratory proteins, as well as their migration and invasiveness potential and capacity to secrete active cytokines
such as the glucose phosphate isomerase/AMF (GPI/AMF). As for the control, the same analysis was also per-
formed in MCF-7 and MDA-MB-231 (highly metastatic, MDA) monolayer cells, and in stage IIIB and IV human
metastatic breast biopsies. The proliferative cell layers (PRL) of mature MCF-7 MCTSs, MDA monolayer cells
andmetastatic biopsies exhibited increased cellular contents (2–15 times) of EMT (β-catenin, SNAIL), migratory
(vimentin, cytokeratin, and ﬁbronectin) and invasive (MMP-1, VEGF) proteins versus MCF-7 monolayer cells,
quiescent cell layers of mature MCF-7 MCTS and non-metastatic breast biopsies. The increase in metastatic
proteins correlated with substantially elevated cellular abilities for migration (18-times) and invasiveness
(13-times) and with the higher level (6-times) of the cytokine GPI/AMF in the extracellular medium of
PRL, as compared to MCF-7 monolayer cells. Interestingly, the addition of the GPI/AMF inhibitors
erythrose-4-phosphate or 6-phosphogluconate at micromolar doses signiﬁcantly decreased its extracellular ac-
tivity (N80%), with a concomitant diminution in the metastatic protein content and migratory tumor cell capac-
ity, and with no inhibitory effect on tumor lactate production or toxicity on 3T3 mouse ﬁbroblasts. The present
ﬁndings provide new insights into the discovery of metabolic inhibitors to be used as complementary therapy
against metastatic and aggressive tumors.
© 2014 Published by Elsevier B.V.1. Introduction
Once tumor metastasis progresses, the response to conventional
anti-cancer therapy signiﬁcantly declines contributing to decrease the
cancer patient's life quality and leading to an increase in fatal outcomes
[1,2]. Therefore, the search for speciﬁc metastasis biomarkers [3] and
in consequence, strategies directed against metastatic progression
has emerged as an urgent need in clinical research [2,4–6]. It has beenpithelial–mesenchymal transi-
roblast growth factor; HDGF,
phate isomerase/autocrine mo-
x metalloproteinases-1; MCTS,
yers; QS, quiescent cell layers;
othelial growth factor; 6PG, 6-
ardiología, Departamento de
an, México DF 14080, Mexico.
6.
uez-Enríquez).
vier B.V.demonstrated that the epithelial–mesenchymal transition (EMT), a
mechanism developed by epithelial cancer cells to acquire a metastatic
phenotype, plays an essential role during solid tumor progression
towards metastasis [7,8]. The EMT onset involves the secretion of some
growth factors such as EGF, HDGF, b-FGF, insulin-like growth factor,
and some cytokines (BMP, TGF-β, and VEGF) [9,10], all of which drive
the metastatic processes through diverse signaling pathways (Snail-1,
Slug, Twist, β-catenin, matrix metalloproteinase, vimentin, N-cadherin,
ﬁbronectin, urokinase PAR receptor, and cytokeratin) and downstream
activation [11,12]. However, these same growth factors and cytokines
are also expelled by some normal cells (keratinocytes and epithelial
cells) during wound healing and tissue regeneration, activating speciﬁc
repair mechanism. Thus, the anti-cancer strategy to block the secretion
of these molecules may result disadvantageously for the host cells
[4,13].
Recently, it has been documented that somemetabolic pathway en-
zymes such as the glucose phosphate isomerase (GPI), when secreted to
the extracellularmilieu, act as a potent cytokine (autocrinemotility fac-
tor, AMF) [14,15]. Although its role as ametastasis inducer has not been
clearly demonstrated, a signiﬁcant increase (4–6 times vs. no EMT-
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brosarcoma and pancreatic carcinoma has been documented, which in
turn promotes the acquisition of metastatic phenotypes [16,17]. In
fact, it has been shown that the use of GPI inhibitors such as
erythrose-4-phosphate or D-mannose-6-phosphate diminishes the
tumor migratory and invasive capacities in bi-dimensional cultures of
several breast cancer lines (SK-BR3, BT-474 and Zr-75R)without appar-
ent effect on normal cells [15,18–21], suggesting that the GPI inhibition
could be a selective strategy to block tumormetastasis. However,mono-
layer cultures cannot accurately reproduce the behavior of cancer cells
within solid tumors regarding the cyclic exposure to O2, glucose, other
nutrients, and growth factors, and the distinct transcriptional and bio-
chemical regulation imposed by the formation of metabolite gradients
between the cell layers near the blood vessels and those localized
more than 100 μm away from them [22,23].
Therefore, the present study focused on elucidating the effect of se-
creted GPI/AMF on EMT, migratory and invasive tumor cell processes in
an experimental model that resembles the initial stages of solid tumor
formation: the multi-cellular tumor spheroids (MCTSs) [24]. In this re-
gard, no studies have been performed in MCTSs where migration, inva-
siveness and EMT are simultaneously analyzed. In addition, the role of
cytokines such as GPI/AMF on tumor migration, invasiveness and EMT
has not been evaluated,which takes relevance considering that its enzy-
matic inhibition by erytrose-4-phosphate or 6-phosphogluconate may
diminish the EMT process and in consequence may block metastatic
progression. In addition, to assess whether the ﬁndings on the acquisi-
tion ofmetastatic phenotype usingMCTSs have physiological relevance,
the GPI/AMF content and EMT and protein migration proﬁles were also
determined in metastatic human breast tumor biopsies (stages IIIB
and IV).2. Material and methods
2.1. Human breast tumor tissue
Ten female patients (from 40 to 80 years old) diagnosed with
inﬁltrating ductal breast carcinoma (IDC) were selected from a cross-
sectional study based in a medical protocol approved by the Ethics
and Research Committees of the Instituto Nacional de Cancerología
(INCAN), México. The patients were punctured with a tru-cut biopsy
needle in the absence of local anesthesia. Histopathology was per-
formed on hematoxylin and eosin stained biopsy slides. Each specimen
was analyzed by visual inspection using standard light microscope by
experimented pathologists [25]. According to routine pathological pro-
cedure to determine Scarf Bloom Richardson differentiation state and
the presence of lymph nodes [26], the 10 samples were classiﬁed as
no-metastatic stage 1 (n= 1); stage IIB (n= 1); potentially metastatic
stage IIIB (n = 7) and metastatic stage IV (n = 1).
Non-tumor tissue was surgically withdrawn from selected areas
of normal breast tissue of the 3 patients and stored in liquid nitrogen
in the INCAN Tumor Bank for 12–24 months [27]. Non-tumor
samples were further validated as non-tumorigenic by assessing
immunohistochemistry (IHC) negativity towards Her2 and hormone
receptor.
Samples from biopsies (0.4–1.8 mg total cellular protein) were
placed in liquid nitrogen and kept at−70 °C until their use. For western
blotting, frozen tumor and normal sampleswere powdered, resuspend-
ed and homogenized in 0.6 mL 25 mM Tris–HCl buffer, pH 7.4, plus
1 mM PMSF (phenyl methanesulfonyl ﬂuoride), 1 mM EDTA and
5 mM DTT, and centrifuged at 2000 g for 30 min at 4 °C. Afterwards,
supernatants were recollected and protein content was determined by
using the Lowry assay. The protein contents of GPI, VEGF, MMP1 and
vimentin were determined (see Western blot assay section below)
with speciﬁc monoclonal antibodies (1:500–1:1000 dilutions; Santa
Cruz Biotechnology, Santa Cruz California, USA).2.2. MCF-7 spheroids formation
Human breast tumor MCF-7 cells (1 × 105/mL) were grown in
Dulbecco-MEM medium supplemented with 10% fetal bovine serum
(GIBCO, Rockville, USA) and 10,000 U penicillin/streptomycin (Sigma;
Steinheim, Germany) and placed in a humidiﬁed atmosphere of
5% CO2/95% air at 37 °C for 3–4 days until conﬂuence of 80–90% was
reached. Afterwards, cells were treated with 0.25% trypsin/EDTA
(GIBCO, Rockville, USA) for 2–3 min and washed by centrifugation
(300 ×g) with fresh PBS [28]. MCF-7 MCTSs were formed from mono-
layer cultures by using the liquid overlaymodiﬁed technique [29]. Brief-
ly, 1 × 105 cells were seeded in 2% (w/v) agarose-coated Petri dishes.
Once spheroids (n = 140) reached a diameter of 100 ± 57 μm (after
5 days of culture), themediumwas replacedwith fresh DMEMmedium
and placed under slow (20–50 rpm) orbital shaking for 14 days at 37 °C
in 95% air/5% CO2. The old medium was replaced with fresh medium
each 2 to 3 days to remove cellular debris and non-formed spheroids.
MCF-7 spheroid size was measured daily with a graduated reticule
(1/10 mm; Zeiss, NY, USA) in an inverted phase contrast microscope
(Zeiss, NY, USA).
2.3. Selective disaggregation of MCF-7 spheroids
MatureMCF-7MCTSs (730±40 μmdiameter; n=120)were recol-
lected at days 16–18 of culture and sequentially trypsinizated by using a
modiﬁed dissociation method [30,31] to separate both external (prolif-
erative, PRL) and internal (quiescent, QS) cellular subpopulations. Brief-
ly, 20–50 spheroidswere exposed to 0.25% trypsin/EDTA solution under
smooth orbital shaking at 37 °C. Two fractions were collected after
3 min of incubation, a rich-proliferative (supernatant) and rich-
quiescent (bottom) cell subpopulations [31]. Afterwards, both cellular
fractions were washed by differential centrifugation at 3400 ×g by
5 min, 37 °C. The cellular bottoms were resuspended in fresh DMEM.
Using the blue trypan method [32], the cellular viability was higher
than 85% and 95% for QS and PRL, respectively. Cellular protein for
western blot assays was determined by using the Biuret method as
previously described [32].
2.4. Cell proliferation and viability assays
Proliferation assays forQS andPRL layerswereperformedas described
elsewhere [31]. Both QS and PRL-rich fractions (5 × 10 cells/mL)
were cultured in DMEM in 24-multiwell plates and incubated at
37 °C. For comparative purposes the proliferation rates of MCF-7
and MDA-MB-231 monolayer cells (both at 5 × 104 cells/mL) were
also determined at 24, 48, 72 and 96 h of culture. Cellular viability
was 87 ± 8 and N95 ± 5% for QS and PRL cell fractions, respectively,
whereas for MCF-7 and MDA-MB-231 monolayer cells viability was
higher than 98%.
2.5. Invasiveness assays
PRL and QS cells from MCF-7 spheroids were placed in the upper
compartment of 96-multiwell Boyden chamber at a ﬁnal concentration
of 5 × 104 cells/well in non-serum DMEM medium (Trevigen Inc.,
Helgerman, USA). After 24 h, the number of cells that have migrated
to the lower chamber compartmentwasdeterminedwith 60nMcalcein
AM (acetomethylester). After 60 min incubation, ﬂuorescence was
detected at 485 nm excitation and 520 nm emission in a microplate
reader (Nunclon TM) [33]. For control assays, MCF-7 and MDA-MB-231
monolayer cells (both at 5 × 104 cells/mL) were used.
2.6. Migration assays
Cellular migration was evaluated by using (A) visualization by light
microscopy of living spindle-like cells well-attached and spread around
1045J.C. Gallardo-Pérez et al. / Biochimica et Biophysica Acta 1843 (2014) 1043–1053the periphery of both MCF-7 young and old MCTSs [34]; and (B) the
wound healing approach in bi-dimensional cultures [35]. For this last
procedure, PRL and QS cells (5 × 105 cells/mL) from MCF-7 spheroids
were cultured in DMEMmedium in bi-dimensional 6-multiwell plates.
After attaining cellular attachment (3–4 h), cell monolayers were
wounded by using a plastic tip [36], washed with 37 °C PBS buffer and
incubatedwith freshnon-serumDMEM.After 8 or 24 h, the oldmedium
was removed and fresh non-serum DMEM was added. Cellular
migration distance from the border to the center of the Petri dish was
measured with a graduate reticule. For control assays, MCF-7 and
MDA-MB-231 monolayer cells (both at 5 × 105 cells/mL) were used.
2.7. Western blot assay
QS and PRL cellular fractions fromMCF-7 spheroids aswell asMCF-7
and MDA monolayer cells were dissolved in RIPA (PBS 1× pH 7.2, 1%
IGEPAL NP40, SDS 0.1% and sodium deoxycholate 0.05%) lysis buffer
plus 5 mM of protease inhibitors cocktail (Roche, Mannheimm,
Germany). Protein samples (40 μg) were resuspended in loading buffer
plus 5% β-mercaptoethanol and loaded onto 12.5% polyacrylamide gel
under denaturalizing conditions [37]. Electrophoretic transfer to PVDF
membranes (BioRad, Hercules, CA, USA) was followed by overnight
immunoblotting with 1:1000 dilution of Ki67, SNAIL, E-cadherin,
β-catenin, VEGF, MMP-1, vimentin, cytokeratin, ﬁbronectin, glucose
phosphate isomerase andα-tubulin antibodies (Santa Cruz Biotechnol-
ogy, Santa Cruz California, USA) at 4 °C. The hybridization bands were
revealed with the corresponding secondary antibodies conjugated
with horseradish peroxidase (Santa Cruz). The signal was detected by
chemi-luminiscence using the ECL-Plus detection system (Amersham
Bioscience, Little Chalfont, Buckinghamshire, UK). Densitometry analy-
sis was performed using the Scion Image Software (Scion, BethesdaMD,
USA) and normalized against its respective load control. Percentage of
each isoform represents the mean ± SD of at least three independent
experiments. The contents of Ki67, SNAIL, E-cadherin, β-catenin,
VEGF, MMP-1, vimentin, cytokeratin, ﬁbronectin, and GPI were ana-
lyzed together with their corresponding α-tubulin as loading control
for each cellular group. Therefore, the composedﬁgureswere generated
with cut blot proteins with their respective α-tubulin.
For detection of GPI, HKII and LDH-A proteins in the medium
supernatant, free-cell medium aliquots of QS and PRL cultures were re-
collected after 24 h and incubated with 10% TCA at 4 °C overnight [38].
Afterwards, precipitated supernatant was centrifuged once at
10,000 rpm for 30 min. Recovered pellets of precipitated supernatants
were resuspended in loading buffer and loaded onto 12.5% SDS-PAGE
gel. Electrophoretic transfer to PVDF membranes (BioRad) was follow-
ed by overnight immunoblotting with 1:500 (GPI/AMF) and 1:1000
(HKII and LDH-A) dilution antibodies (Santa Cruz) at 4 °C. Detection
was performed as described above.
2.8. GPI activity in supernatant of PRL layer
Disaggregated MCF-7 PRL cells (1 × 106 cells/mL) were cultured in
DMEMmedium in 60×15mmPetri dishes for 24h; the cellular number
reachedwas 1.6–1.8× 106 cells/mLwith a viability of 95%. For GPI activ-
ity assays, cell-free culture medium supernatants were incubated in
50 mMMOPS buffer, pH 7.0 plus 2 U glucose-6-phosphate dehydroge-
nase, 1 mM NADP+, at 37 °C. The reaction was started by adding 0.1
(half-saturating) or 2 (saturating) mM fructose-6-phosphate. As con-
trol, HK activity was also determined [39]. Both enzymatic assays
showed no reaction when the speciﬁc substrates were omitted [39].
To determine the time course of GPI secretion, young spheroids
(n= 60, 430 ± 56 μm of diameter) were collected at day 10 of culture
and further incubated in fresh DMEMmedium for 8 days more. At days
10, 12, 14, 16 and 18 of culture, free-spheroids medium was taken for
determination of GPI activity. Also, extracellular GPI activity was deter-
mined in whole spheroids harvested at different times of culture.2.9. GPI/AMF inhibition
Erythrose-4-phosphate (ERI4P, 1, 3, 5 and 10 μM) or 6-
phosphogluconate (6PG, 1, 3, 5, 10 and 12 μM)were added to theme-
dium of PRL and QS bi-dimensional cultures and incubated for 24 h, as
well as to the medium of young MCF-7 spheroids at day 10 of culture
for 6 days more. For young MCTS, the old medium was replaced each
two days with new medium plus inhibitor. Afterwards, determinations
of cellular migration and invasiveness as well as contents of GPI/AMF
and EMT, migration and cellular invasiveness of proteins were
performed as described above. The effect of ERI4P or 6PG (1–50 μM)
was also assayed on 3T3 mouse ﬁbroblast viability for comparative
purposes.
2.10. Extracellular lactate production
The content of L-lactate excreted by MCF-7 PRL cells grown for 24 h
in monolayers in the absence or in the presence of ERI4P or 6PG (3 μM)
was determined spectrophotometrically by using the lactate dehydro-
genase assay in aliquots of culture medium [39]. The external lactate
content was corrected by (i) the intracellular content (2.8–3 × 106
cells) measured in each experimental condition after 24 h and
(ii) subtracting the lactate present in the fresh culture mediumwithout
cells (3.5 mM).
2.11. Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM) of
the indicated number of independent experiments. The experimental
and control groups were statistically compared using an unpaired
two-tailed Student's t-test with P values b0.01 or b0.05 as signiﬁcance
criterion.
3. Results
3.1. Proliferation rates of MCF-7 spheroids PRL and QS cellular layers
Both QS and PRL cellular layers were disaggregated from mature
MCF-7 spheroid (730±40 μmof diameter; n=120; 16–18 days of cul-
ture) and cultured (5 × 104 cells) as monolayers. After 96 h, the cellular
density in the PRL fraction (8.3±0.6 × 105 cells, n= 4)was signiﬁcant-
ly higher (P b 0.05) than in theQS fraction (3.9±0.5 × 105 cells, n=4),
and MCF-7 (5.7 ± 0.3 × 105 cells, n = 4) and MDA-MB-231 (6.6 ± 0.3
× 105 cells, n = 4) monolayers. Indeed, the PRL proliferation rate was
1.3 times higher than the typical highly invasive MDA-MB-231 cells
(Fig. 1A) [40]. After 48 h culture, the PRL cell density (1.8 ± 0.06
× 105 cells, n = 4) was similar to that of MDA-MB-231 cells (1.8 ±
0.2 × 105 cells, n = 4), whereas QS (0.9 ± 0.1 cells, n = 4) and
MCF-7 (1.2 ± 0.2 cells, n = 4) monolayer cell densities were
signiﬁcantly lower.
Accelerated growth of PRL and MDA-MB-231 cell monolayers
correlated with high Ki67 protein levels at 48 h (Fig. 1B) and 96 h
(Supplementary Fig. S1 in Appendix A). These Ki67 levels were signiﬁ-
cantly higher (3–7 times) than those determined for MCF-7 or QS
monolayers (Fig. 1B). Other differences between the PRL and QS cells
were the higher content of p27, a marker of cell quiescence and strong
inhibitor of cyclin/cdk complex, in the latter, conﬁrming that QS cellular
cycle is arrested [31].
3.2. Invasiveness, migratory and EMT proﬁles in PRL and QS mature
spheroid layers
The similar proliferation rates of the PRL fraction and MDA-MB-231
monolayer suggested that PRL cells might have acquired amore aggres-
sive and invasive phenotype than their MCF-7monolayer cells counter-
part. In fact, it has been demonstrated that high proliferation rate in
Fig. 1. (A) Proliferation and (B) western blot of Ki67 protein (48-h culture time-point) of
MCF-7MCTS proliferative (PRL) and quiescent (QS) cell layers cultured as monolayers, as
compared toMCF-7 andMDA-MB-231 (MDA)monolayer cells. *P b 0.05 and **P b 0.01 vs.
PRL, Student t-test for unpaired samples, n = 4 independent preparations.
Fig. 2. Cellular invasiveness (A), migration (B) and wound healing (C) assays of
tumor cells; (D) Images of the wound healing by the PRL layer cells at the indicated
times. *P b 0.05 and **P b 0.01 vs. PRL, n = 4 independent preparations. Abbreviations:
MDA, MDA-MB231; MCTS, multi-cellular tumor spheroid; QS, quiescent; PRL, prolifera-
tive. MDA (▼); PRL (■); QS (●); MCF-7 (▲). Scale bar is 250 μm.
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activation of some signal pathways (NOTCH1, NOTCH3, HES1, MAML1,
DLL-3, and JAG2) evolved in the development of malignant and meta-
static phenotype [41–43]. Therefore, to assess invasive capacity, the
cells were placed on the top of Boyden chambers in the absence of
serum to avoid serum-linked activators [44] and invasiveness was de-
termined after 24 h; for comparisonMCF-7 andMDA-MB-231monolay-
er cells, and QS cell fraction,were also tested. Calcein ﬂuorescence in the
bottom of the chamber revealed the percentage of living and invasive
cells (Fig. 2A) [45].
As expected, and previously demonstrated [46], the MDA-MB-231
monolayer cells showed much higher invasive capacity as compared
to MCF-7 monolayer cells [47]. In contrast, QS and PRL cells, derived
from mature MCTSs, exhibited 4 and 13-times higher invasiveness vs.
MCF-7 monolayer, respectively, indicating that tridimensional organi-
zation in mature spheroids may be involved in the development of cel-
lular invasive capacity. Moreover, cellular layers (internal and external)
derived from young spheroid (430± 56 μm of diameter and 9–11 days
of culture; n= 120) were unable tomigrate (Fig. 2A). Light microscopy
inspection revealed that some highly viable cells detached from 16 day
mature MCTSs acquired ﬁbroblastoid morphology (Fig. 2B, lower
panel). When these detached cells were re-cultured in 24 h-monolayer
conditions, morphology was similar to that observed for human ﬁbro-
blasts (Supplementary Fig. S2 in Appendix A) [48]. A similar behavior
has been described for external cells detaching from tridimensional
models of head, neck and squamous carcinomas [34]. On the contrary,
young spheroids have not acquired the capacity to detach cells from
their external layers (Fig. 2B, upper panel).
To demonstrate whether the invasive capacity correlates with the
acquisition of migratory capacity, the monolayer wound healing test
was assayed (Fig. 2C). Young and mature MCF7 MCTSs were disaggre-
gated in PRL and QS cells. Afterwards, PRL and QS cells, as well as
MCF-7 andMDA-MB-231monolayer cells, were cultured asmonolayers
for 24 h. Once all cellular cultures reached 70–80% conﬂuence, amoder-
ate wound (around 250 μm) was performed with a sterilized tip. After
8–24 h, cellular migration rate was determined measuring the distancefrom the cellular edge. No migration (i.e., less than 10 μm of distance
from the edge) was observed after wounding for both inner and outer
layers isolated from young spheroids (Supplementary Fig. S3 in
Appendix A). On the contrary, the mobility of the PRL MCTSs cells to
the wound healing edge signiﬁcantly increased (2.5 times) from 8 to
24 h (Fig. 2C and D), which was similar to that shown by MDA-MB-
231 cells, a well established migrating tumor cell line [49].
Migration and invasiveness enhanced capacities exhibited by PRL
cells correlated with signiﬁcant increases (2–15 times) in the contents
of invasiveness (MMP-1 and VEGF) and migration (cytokeratin,
ﬁbronectin and vimentin) markers, as compared with QS cells and
MCF-7 monolayer cells, and similar to those observed in MDA-MB-231
monolayer cells (Fig. 3).
EMT is activated as a consequence of acquiring an invasive phenotype
[50]. Indeed, the EMT-associated proteins SNAIL and β-catenin also in-
creased in PRL cells compared to QS (2–4 times), and MCF-7 (SNAIL,
4.5-fold) monolayer cells. In addition, PRL cells showed a signiﬁcant de-
crease of 9–16 times in E-cadherin vs. QS and MCF-7 monolayer cells
(Fig. 3). In turn, similar contents of SNAIL, β-catenin and E-cadherin
were attained by PRL andMDA-MB 231monolayer cells. This phenotype
consisting in enhanced migration, invasiveness and EMT has been also
detected in several aggressive and invasive tumor carcinomas such as
lung adenocarcinoma and cutaneous squamous carcinoma [51,52].
Fig. 3. Proteomic analysis of metastasis proteins. Abbreviations: MMP-1, metalloproteinase-1; VEGF, vascular endothelial growth factor; VIM, vimentin; CK, cytokeratin; FN, ﬁbronectin;
E-CAD, E-cadherin; β-CAT, beta catenin.*P b 0.05 and **P b 0.01 vs. PRL, n = 4 independent preparations.
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human breast cancer biopsies
It has been documented that several carcinomas developing migra-
tory/EMT phenotype such as pulmonary osteosarcoma and breast
cancer secrete the cytokine glucose phosphate isomerase/autocrinemo-
tility factor (GPI/AMF) to the extracellular compartment as part of the
EMT process [20,21]. Therefore, GPI/AMF has been considered as an
EMT biomarker [53]. In order to assess whether PRL layer cells derived
frombreastmatureMCTSs are also able to secrete this cytokine, the pro-
tein content as well as the activity of GPI/AMF were determined in the
cytosolic fraction and free-cell 24-h culture media of PRL and QS layer
cells, as well as in the cytosolic fractions of MCF-7 and MDA-MB-231
monolayer cells and in their extracellular medium (Fig. 4A). To further
establish whether GPI/AMFmay indeed have a role in the EMT andme-
tastasis in realistic clinical breast cancer, biopsies derived fromMexican
patients with ductal inﬁltrating breast carcinoma stages IIIB and IV
(highly metastatic), ductal inﬁltrating carcinoma state IIB (less malig-
nant status) and normal breast tissue were also processed for GPI
protein content determination (Fig. 4B).
The intracellular GPI/AMF protein content was higher in MDA-MB-
231 cells (7–12 times) and PRL layer cells (5–8 times) than in QS layer
and MCF-7 monolayer cells (Fig. 4A). Similarly, the GPI content in the
PRL and MDA-MB-231 free-cell culture media was 2–3 times higher
than that found in QS andMCF-7 cultures as also reported for the extra-
cellular milieu of human osteosarcoma and pancreatic carcinoma after
their metastatic induction [16,20]. To further assess the presence of
this cytokine in the PRL and MDA-MB-231 cell culture supernatants,
the GPI catalytic activity was determined. To demonstrate that exclu-
sively the cells destined to develop the EMT secrete GPI to the milieu,
the activity of another glycolytic enzyme such as hexokinase (HK) was
determined in the cell-free used culture media. A signiﬁcant increase
in the GPI activity (4–5.6-fold) was determined for both MDA-MB-231
monolayer and PRL layer supernatant media, as compared to QS and
MCF-7 monolayer media (Fig. 4C). On the contrary, HK activity
(b1 mU/106 cells, n = 4) as well as HKII and LDH-A protein contents
(Fig. 4A) were not found in any of the assayed media. These observa-
tions clearly indicated that GPI/AMF is actively and speciﬁcally secretedto the extracellularmilieu by cells with metastatic phenotype, and does
not proceed from cell rupture.
Similar to what occurred in PRL layers, the human breast cancer
biopsieswithmalignant state (stage IV) also showed increased contents
of GPI (60-times vs. non-tumor breast tissue) and migration of
proteins (N100-times) MMP-1 and VEGF (Fig. 4B); similar observations
for GPI/AMF and MMP-1 have been reported for human malignant
breast and colorectal cancer biopsies [54,55]. On the contrary, in breast
cancer biopsies with non-malignant phenotype (stages I and IIB) and in
normal non-tumor tissue, low or negligible GPI, MMP-1 and VEGF
contents were found (Fig. 4B).
To demonstrate a relationship between the extracellular content of
kinetically active GPI and the tumor metastatic phenotype, the effect
of the selective and competitive GPI inhibitors ERI4P (1–10 μM) and
6PG (1–12 μM) was tested on (i) the activity of GPI/AMF secreted by
PRL layer and MDA-MB-231 monolayer cells, and (ii) the migration
and invasiveness capacities, and content of metastatic proteins of PRL
layer and MDA-MB-231 monolayer cells (Figs. 4C and 5). In the
presence of 3 μM ERI4P or 3 μM 6PG and half-saturating (0.1 mM, i.e.,
intracellular Fru6P concentration) [39] or saturating (2mM) Fru6P con-
centration, the activity of the secreted GPI (Fig. 4C) was strongly
inhibited by ERI4P (84–100%) and 6PG (88%). The cellular invasiveness
(N40%, Fig. 5A) and migration capacities (N80%, Fig. 5B) of PRL cells
were also signiﬁcantly attenuated by ERI4P or 6PG, without affecting
cellular viability (N95%). Indeed, doses of 1–50 μM ERI4P or 6PG result-
ed innocuously for 24-h viability of normal 3T3 mouse ﬁbroblasts
(Supplementary Fig. S4 in Appendix A). In addition, signiﬁcant diminu-
tion in the contents of SNAIL, β-catenin, VEGF, vimentin, cytokeratin,
ﬁbronectin and MMP-1 in PRL cells was induced by 3 μM ERI4P-
treatment for 24 h, as compared to MCF-7 monolayer cells (Fig. 5C).
In order to demonstrate that migration onset and GPI secretion are
two processes related with the maturity status of solid tumors both
functions were evaluated in young MCF-7 spheroids (Fig. 6) and com-
pared to monolayer MCF-7 cultures (Fig. 4A and C). Young spheroids
(430 ± 56 μm diameter; 10 days of culture) were further cultured in
complete DMEM and cell-free supernatants were collected at the
indicated times (Fig. 6A). GPI secretion from young MCF-7 spheroids
was not apparent at days 10 and 12 of culture. However, signiﬁcant
Fig. 4. (A) GPI/AMF intracellular (cell) and GPI/AMF, LDH-A and HKII extracellular (SN; supernatant) contents of tumor cells; densitometry of intracellular GPI/AMF contents is shown in
right panel; (B) EMT proteomic analysis in no-metastatic stages I (n=1) and IIB (n=1), andmetastatic stages IIIB (n=7) and IV (n=1)ductal inﬁltrating breast carcinomabiopsies, and
breast normal tissue (n=3). **P b 0.01 vs. non-tumor; (C) GPI activity in the extracellularmilieu of bi-dimensional tumor cultures. ERI4Pwas 3 μM. For (A) and (C) *P b 0.05 and **P b 0.01
vs. PRL, n = 3 independent preparations, except for LDH-A and HKII, n = 1. Abbreviations: SN, supernatant; ERI4P, erythrose 4 phosphate; 6PG, 6-phosphogluconate.
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activity (8 and 40-times) at days 16 to 18, suggesting that GPI is actively
secreted to the extracellular milieu only when MCF-7 spheroids are
reaching their maximal diameter andmaturity (730±40 μmdiameter)
(Fig. 6A and B).
This conclusion was further supported by experiments in which the
GPI inhibitors ERI4P or 6PG (3 μM) were added to 10 day-old (young)
spheroids and incubated for 6–8 days more until reaching their mature
spheroid structure. ERI4P or 6PG did not modify the growth rate andﬁnal size of mature spheroids; the ﬁnal diameter reached by mature
ERI4P-treated spheroids was very close to those diameters found in
non-treated mature spheroids (730 ± 40 μm vs. 710 ± 35 μm, respec-
tively). Once ERI4P-treated and non-treated mature spheroids were re-
collected, PRL cellswere isolated and re-cultured asmonolayers for 24 h
(Fig. 6C). As previously described in Fig. 5, PRL cells from non-treated
cells developed an invasive phenotype correlating with the presence
of vimentin and diminution of E-cadherin proteins (Fig. 6D). In contrast,
the PRL cells derived from ERI4P- or 6PG-treated spheroids were unable
Fig. 5. Inhibition of tumor cell migration and invasiveness by erythrose 4-phosphate and
6-phosphogluconate (6PG). PRL layer cells were cultured as monolayers in the absence
and presence of 3 μM ERI4P or 6PG for 24 h. Thereafter, (A) cellular invasiveness (bars)
and lactate produced by tumor cells (■), migration (B) aswell as the content ofmetastatic
proteins (C) were determined, as described in theMaterial andmethods section. Viability
of ERI4P or 6PG-treated cells was higher than 95%. Lactate in the extracellular medium is
expressed in μmol/106 cells; *P b 0.05 and **P b 0.01 vs. PRL, n = 3 independent prepara-
tions. Scale bar in (B) is 200 μm.
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(3-times vs. non-treated cells) contents ofmigratory and EMTproteins.
Furthermore, the production of lactate by PRL cells grown as
monolayers for 24 h in the presence of ERI4P or 6PGwas not signiﬁcant-
ly affected (Fig. 5A), indicating that these GPI inhibitors only affect the
extracellularGPI cytokine functionwithout altering the tumor intracellu-
lar glucosemetabolism, very likely because they are unable to permeate
the plasma membrane.
4. Discussion
4.1. Active EMT, migration and invasiveness in proliferative layers of
mature human breast carcinoma spheroids
The activation of signaling pathways associated with EMT prompts
tumor remodeling for acquisition of malignant phenotypes [19,56]. It
should be noted that EMT, migratory and invasive processes of tumor
cells have been studiedmostly in bi-dimensionalmodels [57], analyzing
only one of these processes and determiningmRNA or protein contents[58]. Therefore, in thepresent study an integral analysis of themigratory
and invasive capacities associated with EMT activation was undertaken
in multi-cellular tumor spheroids (MCTSs), a tumor model resembling
the physiological features found in solid tumors (i.e. cell/cell and cell/
matrix interactions, oxygen and nutrient gradients, drug resistance)
[24]. This integral analysis may provide understanding of the mecha-
nisms triggering tumor migration and invasiveness processes and
guidance in the design of targeted anti-tumorigenic strategies.
The MCTS model provides important advantages over the bi-
dimensional culture frequently used for the study of EMT, migration
and tumor invasion. It has been documented in cervix (HeLa), breast
(MCF-7), glioma (BMG1) and prostate (PC3) carcinoma cells that the
acquisition of 3-D structure induces alterations in the cellular microen-
vironment promoting signiﬁcant changes in the tumor energy metabo-
lism [22,31,59]; proliferation rates [22,31]; transcription factors and
oncogene proﬁle, and drug sensitivity [31,37,60], compared to conven-
tional bi-dimensional cultures.
It has been proposed that the spheroid architecture potentiate the
tumor migratory capacity and the development of more aggressive
phenotypes [34,61]. It also promotes the over-expression of (a) EMT-
associated proteins such as metastasin-1, SNAIL-1 and TGF-β in the
presumably highly proliferative lung mice carcinoma and in colon and
head and neck squamous MCTSs [34,61,62]; and (b) angiogenesis
(VEGF) and differentiation (Kruppel like transcription factor-5)-related
proteins in proliferative layers of HT-29 colon and LNCaP human
prostateMCTSs at levels 3-times higher compared to their counterparts
in monolayer cultures [61,63].
Interestingly, the 3-D conﬁguration of MCF-7 MCTSs enabled spher-
oid periphery cells (whichwould correspond to cells located close to the
blood vessel in in vivo solid tumor) to increase both their proliferation
rate (cf. Fig. 1A) and levels of proteins related to proliferation, EMT, in-
vasiveness and migration (Figs. 1B and 3), at values markedly greater
to those reported for typically highly invasive MDA-MB-231 cells [40],
but similar to those found in human metastatic carcinoma biopsies
(Fig. 4B) [64]. Indeed, the increase in EMT (β-catenin, SNAIL), migratory
(vimentin, cytokeratin and ﬁbronectin) and invasive (MMP-1, VEGF)
proteins, accompanied with the diminution of E-cadherin, in the exter-
nal PRL layers of MCF-7 MCTSs, but not in MCF-7 monolayer cells,
matched with the level of the same proteins found in metastatic solid
biopsies of breast cancer (Fig. 4B), uterine cervical cancer [64] and in ex-
ternal layers of hepatocellular carcinoma MCTSs [65]. Therefore, these
observations indicated that the switch from bi- to tridimensional con-
ﬁguration induces an increase in the tumorigenic properties of the cells.
The levels of N-cadherin and vimentin found in theMCF-7MCTS PRL
layer cellsweremore than2 timeshigher than those found in theMCF-7
monolayer cells pre-stimulated with themetastatic inductor microRNA
miR-21 [66], suggesting that the mechanisms triggered by the 3-D
conﬁguration may also act as tumorigenic inducer.
4.2. Outer layers ofMCF-7MCTSs develop invasive andmigratory phenotypes
Proliferative layers from mature MCF-7 spheroids exhibited en-
hanced EMT, migratory and invasive capacities like those also found in
human malignant breast cancer biopsies (Fig. 4B) and reported for
MCF-7 mamospheres [67], bi-dimensional MDA-MB-231 cells and
EMT-induced colorectal MCTSs [68–70]. In pheochromocytomes and
paragangliomas [71], and colorectal tumor cells [68], the invasive acti-
vation correlated with the increase in MMP-1 and metastatic proteins
such as CD49f, CXCR4, Axin2 and c-met. The migration rates by 24 and
34 h PRL cells (cf. Fig. 2C and D) were similar to those determined for
the highly malignant and invasive stage 4 MDA-MB-231 breast cancer
cells [40] and A431 human epidermal carcinoma cells after metastatic
induction, in which a comparable wound healing migration assay was
used [72]. The enhanced migration ability also correlated with the
VEGF and MMP-1 over-expression in MCTSs PRL cell layers, suggesting
that PRL cells acquire the capacity to remodel their metabolism for
Fig. 6. Effect of erythose 4-phosphate (ERI4P) on (A) GPI content and (B) activity in the supernatant of spheroids after 10 to 18 days of culture. Effect of ERI4P on (C) cellular
invasiveness and (D) EMT and metastatic protein proﬁle of 18 day-old MCF-7 MCTS previously incubated with ERI4P (which was added at day 10 of culture). For comparative
purposes, 6-phosphogluconate (6PG) was also tested. For cellular invasiveness andmigration, ERI4P or 6PG (3 μM)was added to young (10 day-old)MCF-7MCTS andboth cell functions
were determined at day 18 of culture until MCTS reached a maximal diameter of 730 μm. Medium plus inhibitor was replaced each two days of culture. Abbreviations: SN,
supernatant. *P b 0.05 and **P b 0.01 vs. PRL, n = 3 independent preparations.
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static dissemination, in a process similar to that described for MCF-7
MCTSs transplanted into athymic nude mice [73].
4.3. Underlying molecular mechanisms associated with the activation of
EMT and migration processes in human breast cancer
Although the malignant phenotype features are well known, the
molecular mechanisms or intracellular signals associated with the in-
creased contents of EMT,migration and proliferation of proteins trigger-
ing metastasis have not been elucidated. Certainly other processes are
also very likely activated during the metastasis onset, in parallel to thetridimensional formation. During spheroid growth and maturation,
hypoxic areas are developed in the inner spheroid layers [74]. In this re-
gard, it has been established in tumor bi-dimensional cultures that 24 h
hypoxia (7–14 μM O2; [75]) may induce EMT [76], invasive and migra-
tory capacity in tumor cells, through the increase in the levels of VEGF
[77], MMP-1 [78] and the majority of the proteins related to EMT [79].
However, these last observations do not agree with the results
attained with the MCTS inner cell layers (Fig. 3), where the oxygen
availability was certainly scarce, but invasiveness and migration capac-
ities were signiﬁcantly lower to those observed in PRL (outer) layers.
Then, these data suggest that other factors such as nutrient deprivation
may also affect cell motility of inner layers and in consequence
Fig. 7. The GPI inhibitors ERI4P and 6PG block the development of the metastatic
phenotype.
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regard, although no published data on the EMT/invasion/migration and
hypoglycemia relationship are available, it was proposed, based on an
avascular tumor mathematical model of necrosis, a relationship be-
tween prolongednutrient deprivationwith lower invasive andmigrato-
ry potential [80].
An interesting question emerging from the present ﬁndings is
related to the order in which the events occur in the PRL cells for the
development of the metastatic phenotype. Hypoxia per se (mainly by
inducing increased ROS production) seems sufﬁcient to trigger EMT in
HepG2, PANC-1, HT-29, and MCF-7 cancer cells [81]. In contrast, VEGF
is unable to induce EMT at least in HepG2 cells [81]. As PRL cells grow
at all times in a well oxygenated environment, it appears unlikely that
hypoxia may have a relevant role in their EMT. Therefore, it is proposed
that secretion of GPI/AMF, but not hypoxia, triggers the EMT process
and the acquisition of the metastatic phenotype in mature MCTSs.
4.4. Erytrose 4-phosphate, a potent inhibitor of EMT, migratory and
invasive phenotype
One of the principal functions of tumor cells during the EMT onset is
the secretion of cytokines to promote the repression of adhesion mole-
cules [7]. Therefore, several cytokines such as TGF-β, EGF, HDGF, b-FGF,
IL6 and GPI/AMF as well as miR-21 increase (3–5 times) their concen-
trations in the extracellular milieu after EMT/metastases induction
[16]. In consequence, it has been suggested that the inhibition of cyto-
kine secretion might be an alternative strategy for the blockade of
migration and invasiveness of tumor cells [15]. However, several of
these cytokines are also secreted by non-tumor cells. Hence, focus on
GPI/AMF has taken relevance, as this is a cytokine exclusively secreted
by tumor cells but not by normal cells [54,82]. This observation makes
GPI/AMF a potential therapeutic target.
The intracellular and extracellular (Fig. 4A) GPI/AMF contents in
MDA, MCF-7, QS and PRL cells, and metastatic human cancer biopsies
were higher than those found in non-tumor cells [54,82]. Knowing
that GPI/AMF is a strong EMT inductor, the effect of ERI4P or 6PG, potent
GPI inhibitors, on the metastatic processes was evaluated. ERI4P and
6PG competitively inhibit the binding of glucose-6-phosphate to GPI.
However, GPI afﬁnity for ERI4P is 20-times higher than for 6PG
(Ki values of 1 and 20 μM for ERI4P and 6PG, respectively) making
more favorable the clinical use of ERI4P [83]. The presence of extracellular
ERI4P or 6PG diminished the EMT-associated mechanisms for cellular
migration and invasiveness (40% in both cases vs. non-treated cells) as
well as the content of EMT, migratory and invasive proteins. Thus, it
seems that the extracellular ERI4P or 6PG-GPI/AMF complex blocks the
GPI/AMF cellular receptor, diminishing the activation of the transduction
pathways associated with the onset of EMT/migration/invasion (Fig. 7).5. Conclusion
Experimental 3-D models of solid tumors such as MCTSs allow
(i) the identiﬁcation and development of processes, not apparent in
monolayer cultures, which promote malignant phenotypes in pre-
metastatic lesions; and (ii) to envision biochemical strategies for
blocking the acquisition of a metastatic phenotype in cancer cells by
selective drugs that do not affect non-tumor cells.
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